From: Economic burden of antibiotic resistance in China: a national level estimate for inpatients
Baseline characteristics | Before PSM | After PSM | ||||
---|---|---|---|---|---|---|
Susceptible | SDR | P- value | Susceptible | SDR | P value | |
Number of inpatients, n | 3163 | 5459 | 3135 | 3135 | ||
Age in year, median (Min–Max) | 68 (0–100) | 73 (0–100) | < 0.000 | 68 (0–100) | 69 (0–100) | 0.994 |
Sex male, n (%) | 1904 (60.2) | 3324 (60.9) | 0.525 | 1881 (60.0) | 1873 (59.7) | 0.837 |
Insurance, n (%) | 2529 (80.0) | 4727 (86.6) | < 0.000 | 2525 (80.5) | 2526 (80.6) | 0.975 |
Number of diagnosis, median (Min–Max) | 6 (1–36) | 6 (1–30) | 0.0002 | 6 (1–36) | 6 (1–30) | 0.925 |
CCI, median (Min–Max) | 5 (1–37) | 5 (1–33) | < 0.000 | 5 (1–37) | 5 (1–33) | 0.815 |
Admission to ICU, n (%) | 335 (10.6) | 415 (7.6) | < 0.000 | 329 (10.5) | 321 (10.2) | 0.740 |
Surgery, n (%) | 923 (29.2) | 1161 (21.3) | < 0.000 | 904 (28.8) | 920 (29.4) | 0.656 |
Myocardial infraction, n (%) | 92 (2.9) | 125 (2.3) | 0.077 | 90 (2.9) | 85 (2.7) | 0.701 |
Congestive heart failure, n (%) | 620 (19.6) | 959 (17.6) | 0.019 | 603 (19.2) | 611 (19.5) | 0.798 |
Peripheral vascular disease, n (%) | 45 (1.4) | 48 (0.9) | 0.019 | 41 (1.3) | 39 (1.2) | 0.822 |
Cerebrovascular diseases, n (%) | 1428 (45.2) | 2665 (48.8) | 0.001 | 1423 (45.4) | 1369 (43.7) | 0.170 |
Dementia, n (%) | 45 (1.4) | 254 (4.7) | < 0.000 | 45 (1.4) | 40 (1.3) | 0.585 |
Chronic pulmonary disease, n (%) | 969 (30.6) | 1388 (25.4) | < 0.000 | 960 (30.6) | 969 (30.9) | 0.805 |
Connective tissue disease, n (%) | 80 (2.5) | 132 (2.4) | 0.748 | 80 (2.6) | 75 (2.4) | 0.684 |
Mild liver disease, n (%) | 109 (3.5) | 194 (3.6) | 0.794 | 109 (3.5) | 122 (3.9) | 0.383 |
Peptic ulcer disease, n (%) | 69 (2.2) | 141 (2.6) | 0.244 | 69 (2.2) | 65 (2.1) | 0.727 |
Diabetes mellitus, n (%) | 795 (25.1) | 1546 (28.3) | 0.001 | 795 (25.4) | 813 (25.9) | 0.603 |
Diabetes mellitus with chronic complication, n (%) | 112 (3.5) | 242 (4.4) | 0.044 | 112 (3.6) | 104 (3.3) | 0.580 |
Moderate to severe chronic kidney disease, n (%) | 212 (6.7) | 447 (8.2) | 0.012 | 211 (6.7) | 217 (6.9) | 0.764 |
Hemiplegia, n (%) | 20 (0.6) | 54 (1.0) | 0.083 | 20 (0.6) | 17 (0.5) | 0.621 |
Solid tumor without metastases, n (%) | 223 (7.1) | 425 (7.8) | 0.212 | 223 (7.1) | 233 97.4) | 0.627 |
Leukemia, n (%) | 37 (1.2) | 66 (1.2) | 0.872 | 37 (1.2) | 38 (1.2) | 0.908 |
Malignant lymphoma, n (%) | 24 (0.8) | 50 (0.9) | 0.446 | 24 (0.8) | 27 (0.9) | 0.673 |
Severe liver disease, n (%) | 34 (1.1) | 81 (1.5) | 0.111 | 34 (1.1) | 36 (1.2) | 0.810 |
Metastatic tumor, n (%) | 137 (4.3) | 304 (5.6) | 0.012 | 137 (4.4) | 133 (4.2) | 0.803 |